Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tazarotene + clindamycin is a combination therapy used for the treatment of acne vulgaris. Tazarotene is an acetylenic retinoid that normalizes keratinocyte differentiation and has anti-inflammatory properties. Clindamycin is a topical antibiotic that works by killing bacteria that cause acne and reducing inflammation. When used together, these medications provide complementary mechanisms of action that enhance efficacy against both inflammatory and non-inflammatory acne lesions. Clinical studies have shown that this combination offers significantly greater efficacy than other retinoid-antibiotic combinations such as tretinoin + clindamycin or adapalene + clindamycin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tazarotene + clindamycin.